We present the case of a 56-year-old male patient with advanced NSCLC harboring a canonical EGFR mutation who was treated with chemotherapy in conjunction with amivantamab and developed amivantamab-induced myocardial injury in the absence of thrombotic events. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.